L26/P-821 Beyond the Algorithm: Conventional Dose of Follitropin Delta for Blastocyst Banking in Chinese Freeze-All Cycles
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von Q. Xu und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Study question In planned freeze-all IVF/ICSI cycles, does conventional follitropin delta dosing exceeding the algorithm optimize blastocyst yield without compromising oocyte competence in Chinese patients? Summary answer In planned freeze-all cycles, dosing beyond the algorithm (mean +3.27 μg) was associated with increased blastocysts without compromise in oocyte developmental competence or safety outcomes. What is known already Follitropin delta algorithms aim to achieve retrieval of 8-14 oocytes to minimize ovarian hyperstimulation syndrome (OHSS). However, freeze-all strategies combined with GnRH agonist triggering substantially reduce this risk. As cumulative live birth rates increase proportionally with oocyte yield, the appropriateness of conservative dosing has been questioned. Whether conventional dosing strategies in Chinese patients undergoing freeze-all cycles can enhance blastocyst yield without compromising oocyte competence remains unclear. Study design, size, duration This single-center retrospective cohort study included 219 women undergoing IVF/ICSI cycles using a freeze-all strategy at the Reproductive Center of the First Affiliated Hospital of Anhui Medical University. All participants received controlled ovarian stimulation with follitropin delta administered under either a GnRH antagonist protocol or an early follicular long GnRH agonist protocol. Participants/materials, setting, methods All patients underwent IVF/ICSI using follitropin delta within either a GnRH antagonist or GnRH agonist protocol. For each patient, an “algorithm dose” was calculated based on body weight and AMH level. The primary endpoint was the number of cryopreserved blastocysts. Secondary endpoints included clinical pregnancy rate, number of total oocyte, number of metaphase II (MII) oocytes, fertilization rate, total number of cryopreserved blastocysts, oocyte utilization rate,and the incidence of OHSS. Main results and the role of chance In this retrospective analysis of 219 patients (average age 31.1 ± 3.8 years; mean AMH 4.65 ± 2.36 ng/mL), the conventional follitropin delta dose (12.10 ± 2.52 μg) significantly exceeded the calculated algorithm target (8.84 ± 1.89 μg; difference +3.27 μg, P < 0.001). This dosing strategy yielded 15.3 ± 7.7 oocytes, and 6.6 ± 4.2 cryopreserved blastocysts, surpassing benchmarks reported in the China subgroup of the GRAPE study (10.3 ± 6.2 oocytes; 4.4 ± 3.8 Day 3 good-quality embryos). Importantly, oocyte developmental competence remained preserved, with a fertilization rate of 81.6% and an oocyte utilization rate of 42.3%. Regarding clinical efficacy, the study demonstrated robust pregnancy outcomes, achieving clinical pregnancy rates of 73.21% per transfer cycle. No cases of OHSS were observed. Among patients of advanced maternal age (≥35 years; n = 41), higher dosing (13.24 ± 2.06 μg) maintained favorable outcomes, yielding 5.5 ± 3.8 blastocysts and an oocyte utilization rate of 39.5% ± 22.2%. Collectively, these findings suggest that a dosing strategy exceeding the algorithm target can optimize cumulative reproductive potential while maintaining a favourable safety profile. Limitations, reasons for caution Additional longitudinal follow-up is required to determine whether increased blastocyst yield translates into improved cumulative live birth rates (CLBR) in this Chinese cohort. Wider implications of the findings Within planned freeze-all cycles, algorithm-based follitropin delta dosing may be overly conservative. A High-Yield stimulation strategy may facilitate efficient blastocyst banking, potentially shortening time to pregnancy and reducing treatment burden by maximizing embryo availability from a single stimulation cycle. Trial registration number No
Zitieren
APA
Xu, Q., Xiang, H., Xu, Y., Xing, Q., & Cao, Y. (2026). L26/P-821 Beyond the Algorithm: Conventional Dose of Follitropin Delta for Blastocyst Banking in Chinese Freeze-All Cycles. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1148
Vancouver
Xu Q, Xiang H, Xu Y, Xing Q, Cao Y. L26/P-821 Beyond the Algorithm: Conventional Dose of Follitropin Delta for Blastocyst Banking in Chinese Freeze-All Cycles. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1148
BibTeX
@article{Xu2026,
author = {Xu, Q. and Xiang, H. and Xu, Y. and Xing, Q. and Cao, Y.},
title = {L26/P-821 Beyond the Algorithm: Conventional Dose of Follitropin Delta for Blastocyst Banking in Chinese Freeze-All Cycles},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1148}
}
EUVIMED